Skip to main content

Table 3 Scenario analyses of lower dosing

From: Pharmacokinetic parameter driven outcomes model predicts a reduction in bleeding events associated with BAY 81–8973 versus antihemophilic factor (recombinant) plasma/albumin-free method in a Chinese healthcare setting

  Dosing 25 IU/kg (base case) Dosing 20 IU/kg Dosing 15 IU/kg
Costs
 BAY 81–8973 ¥16,930,390 ¥13,703,193 ¥10,487,104
 rAHF-PFM ¥17,052,210 ¥13,821,831 ¥10,599,846
Incremental cost -¥121,819 -¥118,638 -¥112,742
QALYs
 BAY 81–8973 13.220 13.202a 13.179a
 rAHF-PFM 13.167 13.151a 13.132a
Incremental QALYs 0.053 0.050 0.047
ICER BAY 81–8973 is dominant (lower costs and higher QALY gain)
  1. aDerived using the annual bleeding rate of 25 IU/kg
  2. ICER incremental cost-effectiveness ratio, rAHF-PFM: antihemophilic factor (recombinant) plasma/albumin-free method; QALYs: quality-adjusted life years